Hemcheck´s Newsletter - May 2020

Welcome to the May newsletter from Hemcheck

May has been an interesting month for many reasons. We are taking steps forward despite the ongoing pandemic through e.g. discussions with potential customers, a new signed agreement, and the completion of various development activities. The Pandemic situation continues to affect us as earlier communicated.

Something we are particularly proud of this month is that we have signed an evaluation agreement with Hemakim regarding potential distribution in Turkey, which is an interesting and large market.

We have also been selected to participate in the EIT's Bridgehead Europe program which will strengthen our commercialization opportunities in selected countries outside the Nordics.

On May 14, we had our Annual General Meeting, which was held in Karlstad. More about this can be found below.

Enjoy the reading!
Joen Averstad, CEO


Agreement signed with Hemakim for potential distribution in Turkey

Hemcheck has signed a 3-month evaluation agreement, starting in June 2020, with potential continuation into a 33-month long distribution agreement with Hemakim Tibbi Ürünler San.Ve Tic. A.S (”Hemakim”), one of the leading distributors of medical equipment in Turkey. The agreement is formed to evaluate the collaboration and market opportunity and will be exclusive for the Turkish market, provided that the evaluation be successful according to both parties. Hemakim has committed to an initial purchase order of readers and one-time tests for a value of 10 000 EUR, provided that the agreement is extended after the 3-month evaluation period.

– Hemakim is well established in the local market to which the agreement applies, and they have shown a lot of interest in Hemcheck and the potential of our products. We look forward to working with Hemakim and hope that the evaluation period will be successful and that this will turn into a long-term collaboration, says Joen Averstad, CEO of Hemcheck.

Read more


Interview Analyst Group

Joen has been interviewed by an external analysis company. The interview was about the agreement with Synlab and what potential he sees for further areas of cooperation, how HemCheck is affected by SARS-CoV-2
and what he would highlight about HemCheck to an investor who is particularly interesting to monitor during 2020.

Read the full interview here.

HemCheck's Annual General Meeting

The Meeting was effectively performed and had few participants, likely given the pandemic situation. The Meeting decided in line with all proposals that had been communicated beforehand.

Jenni Björnulfson, Anna Dalgaard, Hjalmar Didrikson, Karin Dahllöf, and Torbjörn Koivisto were re-elected as Board members.

Read more

Hemcheck selected as a participant in EIT Health Bridgehead Europe program

Hemcheck has been selected as one of ca 30 participants to participate in EIT Health Bridgehead Europe program, to support internationalization.

- Being selected shows that important decision-makers in other countries see our solutions as interesting and that there is good market potential in other European countries, says Joen Averstad, CEO Hemcheck.

Read more

Update on the SARS-CoV-2 situation

We are experiencing the same impact as earlier communicated. Examples are that all trade fairs scheduled to take place before the summer are postponed or canceled, some customer meetings and tests have gotten postponed and we work more from home than before the pandemic. There has not been any impact on our supply chain and we do not experience any shift in interest for our products in any way (negative or positive) due to the situation. We continue to monitor the situation carefully, including commercial opportunities, and hope things will return to a more normal state after the summer.

Calendar of upcoming events

June 30 - 1 July - Bridgehead Europe matchmaking event
Sep 02- LINUS-days
Sep 02- Labdays 2020
Kontakta oss
HemCheck Sweden AB
Karlstads universitet
Universitetsgatan 2
651 88 Karlstad